SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 78094.64
166.49 (0.21%)

Filter

Top Pharma Companies in India as on Aug-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
1	Sun Pharmaceutical Industries Ltd.	Q V+ PT	4,77,312 Large Cap	1,989.35 (-0.57%)	39.46	5.52	11.78	14.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
2	Divis Laboratories Ltd.	Q V+ PT	2,13,879 Large Cap	8,056.65 (2.76%)	73.12	12.11	8.67	4.44	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
3	Torrent Pharmaceuticals Ltd.	Q V+ PT	1,94,094 Large Cap	5,102.80 (4.77%)	88.99	21.63	11.80	13.74	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
4	Apollo Hospitals Enterprise Ltd.	Q V+ PT	1,28,759 Large Cap	8,955 (-0.35%)	86.27	12.97	-3.49	29.94	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
5	Cipla Ltd.	Q V PT	1,18,993 Mid Cap	1,472.95 (0.47%)	35.3	3.38	8.01	10.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
6	Zydus Lifesciences Ltd.	Q V PT	1,12,369 Mid Cap	1,126.50 (0.99%)	22.3	4.32	13.52	14.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
7	Lupin Ltd.	Q V PT	1,10,374 Mid Cap	2,413.95 (-0.21%)	20.7	4.93	13.02	32.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
8	Max Healthcare Institute Ltd.	Q V PT	1,06,919 Mid Cap	1,098.55 (-2.48%)	74.13	10.08	27.27	155.29	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
9	Mankind Pharma Ltd.	Q V PT	1,02,006 Mid Cap	2,469.90 (-4.15%)	46.78	6.03	13.54	13.36	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
10	Laurus Labs Ltd.	Q V+ PT	98,126 Mid Cap	1,816.10 (1.95%)	89.75	17.4	7.19	-2.25	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
11	Dr. Reddys Laboratories Ltd.	Q V+ PT	95,787 Mid Cap	1,147.60 (0.28%)	29.73	2.51	12.09	15.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
12	Aurobindo Pharma Ltd.	Q V+ PT	90,872 Mid Cap	1,579.35 (0.25%)	37.63	4	-3.95	-0.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
13	Aster DM Quality Care Ltd.	Q V+ PT	71,638 Mid Cap	821.85 (0.94%)	184.57	14.53	-13.71	0.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
14	Fortis Healthcare Ltd.	Q V+ PT	71,328 Mid Cap	944.80 (-0.38%)	309.66	7.73	23.15	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
15	Biocon Ltd.	Q V PT	69,368 Mid Cap	425.65 (0.02%)	1864.73	2.54	2.96	-18.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
16	Alkem Laboratories Ltd.	Q V+ PT	68,784 Mid Cap	5,752.85 (-1.09%)	31.48	4.91	6.01	5.86	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
17	Glenmark Pharmaceuticals Ltd.	Q V+ PT	63,024 Mid Cap	2,233.30 (1.93%)	35.05	5.73	4.60	14.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
18	Abbott India Ltd.	Q V PT	59,039 Mid Cap	27,784.15 (0.79%)	38.04	12.44	9.96	17.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
19	Anthem Biosciences Ltd.	Q V PT	45,564 Mid Cap	808.75 (3.22%)	72.99	14	13.62	19.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
20	Glaxosmithkline Pharmaceuticals Ltd.	Q V+ PT	44,951 Mid Cap	2,653.45 (1.68%)	43.39	19.69	5.49	17.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
21	Ipca Laboratories Ltd.	Q V+ PT	44,326 Mid Cap	1,747.15 (-0.81%)	39.14	5.56	7.35	1.36	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
22	Ajanta Pharma Ltd.	Q V+ PT	43,362 Mid Cap	3,470.10 (1.19%)	38.21	8.93	13.54	10.92	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
23	Narayana Hrudayalaya Ltd.	Q V PT	41,435 Mid Cap	2,027.55 (-2.49%)	50.77	8.73	25.04	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
24	Gland Pharma Ltd.	Q V PT	41,314 Small Cap	2,504.40 (-0.42%)	31.79	3.84	9.35	7.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
25	Global Health Ltd.	Q V PT	37,868 Small Cap	1,408.40 (-0.51%)	78.64	9.11	16.83	34.86	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
26	Emcure Pharmaceuticals Ltd.	Q V+ PT	37,099 Small Cap	1,955.85 (2.40%)	50.61	10	13.02	9.98	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
27	Krishna Institute of Medical Sciences Ltd	Q V PT	33,790 Small Cap	804.50 (-0.35%)	129.61	8.6	11.87	17.04	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
28	Dr. Lal Pathlabs Ltd.	Q V PT	31,977 Small Cap	1,907.50 (1.55%)	58.69	12.43	12.18	13.26	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
29	Wockhardt Ltd.	Q V+ PT	31,850 Small Cap	1,960.10 (2.79%)	149.53	6.46	4.49	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
30	Sai Life Sciences Ltd.	Q V+ PT	27,940 Small Cap	1,316.10 (0.13%)	81.82	11.14	17.75	11.20	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Fermenta Biotech	501.25	7.67%
Concord Biotech	1,420.30	6.53%
Alivus Life Sciences	1,159.20	5.82%
Park Medi World	293.40	5.12%
Torrent Pharma	5,102.80	4.77%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Strides Pharma Scien	1,023.25	-4.67%
Mankind Pharma	2,469.90	-4.15%
Acutaas Chemicals	3,099.95	-4.13%
Onesource Specialty	1,621.75	-3.69%
Shree Ganesh Remed.	631.75	-3.43%

News about Top Pharma Companies in India

Aug, 2026

Zydus Lifesciences gets EIR from USFDA for injectable facility in Ahmedabad

The GMP surveillance inspection was conducted from April 27 to May 05, 2026

Aug, 2026

Divis Laboratories informs about outcome of board meeting

Further to letter dated July 20, 2026, Divis Laboratories has informed that the Board of Directors of the Company at its meeting held on August 01, 2026, has approved the unaudited financial results for the quarter ended June 30, 2026; Appointment of Senior Management Personnel Approved appointment of B. Vara Prasad, General Manager (Engineering Purchase) and J. Srinivasa Rao, General Manager (Raw Materials Purchase) as Senior Management Personnel of the Company as recommended by the Nomination and Remuneration Committee, with effect from August 01, 2026.

The above information is a part of company’s filings submitted to BSE.

Aug, 2026

Dr. Reddy's Laboratories gets USFDA’s approval for rituximab biosimilar

The approval further strengthens its growing global biosimilars portfolio and advances its biosimilars business in the United States

Aug, 2026

Dr. Reddy’s Laboratories informs about press release

Dr. Reddy’s Laboratories has informed that it enclosed a Press Release, ‘Dr. Reddy's Laboratories Receives U.S. FDA Approval for Rituximab Biosimilar’.

The above information is a part of company’s filings submitted to BSE.

Aug, 2026

Sun Pharma. Inds. - Quaterly Results

The company's total revenue for the quarter ended June 2026 saw a slight change in the total revenue, having registered a total revenue of Rs. 57411.30 millions.A comparatively good net profit growth of 49.67% to Rs. 11151.40 millions was reported for the quarter ended June 2026 compared to Rs. 7450.60 millions of previous same quarter.Operating profit surged to 21043.80 millions from the corresponding previous quarter of 20132.40 millions.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	57411.30	55948.80	2.61	57411.30	55948.80	2.61	207546.40	229774.00	-9.67
Other Income	1401.70	1037.10	35.16	1401.70	1037.10	35.16	4193.30	3791.40	10.60
PBIDT	21043.80	20132.40	4.53	21043.80	20132.40	4.53	66000.20	72168.40	-8.55
Interest	2784.80	2384.20	16.80	2784.80	2384.20	16.80	9478.40	9538.90	-0.63
PBDT	17943.70	14871.80	20.66	17943.70	14871.80	20.66	51058.40	62629.50	-18.48
Depreciation	3079.20	3109.20	-0.96	3079.20	3109.20	-0.96	13117.20	12867.40	1.94
PBT	14864.50	11762.60	26.37	14864.50	11762.60	26.37	37941.20	49762.10	-23.75
TAX	3713.10	4312.00	-13.89	3713.10	4312.00	-13.89	11707.00	7481.30	56.48
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PAT	11151.40	7450.60	49.67	11151.40	7450.60	49.67	26234.20	42280.80	-37.95
Equity	2399.30	2399.30	0.00	2399.30	2399.30	0.00	2399.30	2399.30	0.00
PBIDTM(%)	36.65	35.98	1.86	36.65	35.98	1.86	31.80	31.41	1.25

Jul, 2026

Sun Pharma reports 27% rise in Q1 consolidated net profit

Consolidated total income of the company increased by 11.93% to Rs 16,023.50 crore for Q1FY27

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Sun Pharmaceutical Industries Ltd.	4,77,312 Crore
2	Divis Laboratories Ltd.	2,13,879 Crore
3	Torrent Pharmaceuticals Ltd.	1,94,094 Crore
4	Apollo Hospitals Enterprise Ltd.	1,28,759 Crore
5	Cipla Ltd.	1,18,993 Crore
6	Zydus Lifesciences Ltd.	1,12,369 Crore
7	Lupin Ltd.	1,10,374 Crore
8	Max Healthcare Institute Ltd.	1,06,919 Crore
9	Mankind Pharma Ltd.	1,02,006 Crore
10	Laurus Labs Ltd.	98,126 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	27,784	59,039	38.04	12.44	26.05	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	5,103	1,94,094	88.99	21.63	40.56	29.04
Lupin Ltd. (M)	Somewhat Good	2,414	1,10,374	20.70	4.93	11.97	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,470	43,362	38.21	8.93	25.82	25.35
Laurus Labs Ltd. (M)	Very Good	1,816	98,126	89.75	17.40	48.10	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,816	98,126	108
Sai Life Sciences Ltd. (S)	Very Good	1,316	27,940	62.66
Aurobindo Pharma Ltd. (M)	Very Good	1,579	90,872	38.42
Torrent Pharmaceuticals Ltd. (L)	Very Good	5,103	1,94,094	36.37
Ajanta Pharma Ltd. (M)	Very Good	3,470	43,362	26.15
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,316	27,940	81.82	11.14	43.03	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,470	43,362	38.21	8.93	25.82	13.54
Mankind Pharma Ltd. (M)	Very Good	2,470	1,02,006	46.78	6.03	29.65	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,127	1,12,369	22.30	4.32	13.66	13.52
Lupin Ltd. (M)	Somewhat Good	2,414	1,10,374	20.70	4.93	11.97	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,414	1,10,374	20.70	4.93	11.97	32.37
Abbott India Ltd. (M)	Very Good	27,784	59,039	38.04	12.44	26.05	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,148	95,787	29.73	2.51	15.26	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,127	1,12,369	22.30	4.32	13.66	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,989	4,77,312	39.46	5.52	23.40	14.41

You have 9 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Zydus Lifesciences gets EIR from USFDA for injectable facility in Ahmedabad

Divis Laboratories informs about outcome of board meeting

Dr. Reddy's Laboratories gets USFDA’s approval for rituximab biosimilar

Dr. Reddy’s Laboratories informs about press release

Sun Pharma. Inds. - Quaterly Results

Sun Pharma reports 27% rise in Q1 consolidated net profit

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.